AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518 IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Brief description of study

If you or your child have been diagnosed with B-Acute Lymphoblastic Leukemia (B-ALL) that has relapsed or is refractory. Relapse means that the cancer has come back after treatment. Refractory means that the cancer has not responded to treatment. The main goal of this phase 2 study is to learn more about how to treat B-ALL when it has come back. During this study, we will test whether the relapsed B-ALL responds to a new drug called inotuzumab ozogamacin (InO).

Clinical Study Identifier: s17-01042
ClinicalTrials.gov Identifier: NCT02981628
Principal Investigator: Sharon L Gardner.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.